Early use of insulin in type 2 diabetes

Roy Eldor; Erwin Stern; Zvonko Milicevic; Itamar Raz

doi:10.1016/j.diabres.2005.03.004

Early use of insulin in type 2 diabetes

Roy Eldor^*, Erwin Stern, Zvonko Milicevic, Itamar Raz

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Type 2 diabetes is a disease characterised by peripheral insulin resistance, as well as by pancreatic beta cell dysfunction. This process is in part due to elevated blood glucose and free fatty acids - termed glucolipotoxicity. The traditional pathway of treating type 2 diabetes in a stepwise manner, beginning with life style modifications and continuing with oral hypoglycaemic agents leads to a protracted period of unnecessary hyperglycaemia. A new approach, targeted at alleviating the deleterious effects of hyperglycaemia and elevated free fatty acids by acutely lowering both with intensive insulin therapy, has yielded prolonged remissions in therapy in which only diet was necessary to maintain normoglycaemia. This new approach, its rationale, benefits and misgivings are discussed in this review.

Original language	English
Pages (from-to)	S30-S35
Journal	Diabetes Research and Clinical Practice
Volume	68
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/j.diabres.2005.03.004
State	Published - Jun 2005
Externally published	Yes

Keywords

Diabetes mellitus type 2
Early insulin treatment
Glucotoxicity
Hypoglycemia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diabres.2005.03.004

Cite this

@article{b4f002f483fd4a82995658cfab5b79af,

title = "Early use of insulin in type 2 diabetes",

abstract = "Type 2 diabetes is a disease characterised by peripheral insulin resistance, as well as by pancreatic beta cell dysfunction. This process is in part due to elevated blood glucose and free fatty acids - termed glucolipotoxicity. The traditional pathway of treating type 2 diabetes in a stepwise manner, beginning with life style modifications and continuing with oral hypoglycaemic agents leads to a protracted period of unnecessary hyperglycaemia. A new approach, targeted at alleviating the deleterious effects of hyperglycaemia and elevated free fatty acids by acutely lowering both with intensive insulin therapy, has yielded prolonged remissions in therapy in which only diet was necessary to maintain normoglycaemia. This new approach, its rationale, benefits and misgivings are discussed in this review.",

keywords = "Diabetes mellitus type 2, Early insulin treatment, Glucotoxicity, Hypoglycemia",

author = "Roy Eldor and Erwin Stern and Zvonko Milicevic and Itamar Raz",

year = "2005",

month = jun,

doi = "10.1016/j.diabres.2005.03.004",

language = "אנגלית",

volume = "68",

pages = "S30--S35",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Early use of insulin in type 2 diabetes

AU - Eldor, Roy

AU - Stern, Erwin

AU - Milicevic, Zvonko

AU - Raz, Itamar

PY - 2005/6

Y1 - 2005/6

N2 - Type 2 diabetes is a disease characterised by peripheral insulin resistance, as well as by pancreatic beta cell dysfunction. This process is in part due to elevated blood glucose and free fatty acids - termed glucolipotoxicity. The traditional pathway of treating type 2 diabetes in a stepwise manner, beginning with life style modifications and continuing with oral hypoglycaemic agents leads to a protracted period of unnecessary hyperglycaemia. A new approach, targeted at alleviating the deleterious effects of hyperglycaemia and elevated free fatty acids by acutely lowering both with intensive insulin therapy, has yielded prolonged remissions in therapy in which only diet was necessary to maintain normoglycaemia. This new approach, its rationale, benefits and misgivings are discussed in this review.

AB - Type 2 diabetes is a disease characterised by peripheral insulin resistance, as well as by pancreatic beta cell dysfunction. This process is in part due to elevated blood glucose and free fatty acids - termed glucolipotoxicity. The traditional pathway of treating type 2 diabetes in a stepwise manner, beginning with life style modifications and continuing with oral hypoglycaemic agents leads to a protracted period of unnecessary hyperglycaemia. A new approach, targeted at alleviating the deleterious effects of hyperglycaemia and elevated free fatty acids by acutely lowering both with intensive insulin therapy, has yielded prolonged remissions in therapy in which only diet was necessary to maintain normoglycaemia. This new approach, its rationale, benefits and misgivings are discussed in this review.

KW - Diabetes mellitus type 2

KW - Early insulin treatment

KW - Glucotoxicity

KW - Hypoglycemia

UR - https://www.scopus.com/pages/publications/20444363109

U2 - 10.1016/j.diabres.2005.03.004

DO - 10.1016/j.diabres.2005.03.004

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 15955372

AN - SCOPUS:20444363109

SN - 0168-8227

VL - 68

SP - S30-S35

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

IS - SUPPL. 1

ER -

Early use of insulin in type 2 diabetes

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this